• 1. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidine carboxylic acids and derivatives Pyrrolidine carboxylic acids

Recent Advances in the Study of Ethyl 3-(Propan-2-yl)Pyrrolidine-3-Carboxylate (CAS: 1692722-15-8)

Ethyl 3-(propan-2-yl)pyrrolidine-3-carboxylate (CAS: 1692722-15-8) is a compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have highlighted its potential as a versatile intermediate in the synthesis of bioactive molecules, particularly in the development of novel therapeutic agents. This research briefing provides an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug discovery.

The compound's unique pyrrolidine scaffold, combined with the isopropyl and ester functional groups, makes it a valuable building block for medicinal chemistry. Recent literature has explored its role in the synthesis of small molecule inhibitors targeting various enzymes and receptors. For instance, a study published in the Journal of Medicinal Chemistry demonstrated the use of ethyl 3-(propan-2-yl)pyrrolidine-3-carboxylate as a key intermediate in the development of selective kinase inhibitors, which show promise in oncology applications.

In addition to its synthetic utility, the biological activity of ethyl 3-(propan-2-yl)pyrrolidine-3-carboxylate has been investigated in several preclinical models. Research indicates that derivatives of this compound exhibit moderate to high binding affinity for certain G protein-coupled receptors (GPCRs), suggesting potential applications in neurological and cardiovascular diseases. A recent study in Bioorganic & Medicinal Chemistry Letters reported the optimization of this scaffold to enhance its pharmacokinetic properties, resulting in improved bioavailability and metabolic stability.

From a methodological perspective, advances in asymmetric synthesis have enabled the efficient production of enantiomerically pure forms of ethyl 3-(propan-2-yl)pyrrolidine-3-carboxylate. This is particularly important given the increasing emphasis on chirality in drug development. A 2023 publication in Organic Letters detailed a novel catalytic system that achieves high enantioselectivity in the synthesis of this compound, offering a scalable route for industrial applications.

Looking ahead, the versatility of ethyl 3-(propan-2-yl)pyrrolidine-3-carboxylate positions it as a compound of continued interest in pharmaceutical research. Ongoing studies are exploring its incorporation into larger molecular architectures, such as peptidomimetics and macrocycles, to target challenging biological pathways. Furthermore, computational modeling approaches are being employed to predict new derivatives with enhanced therapeutic potential. The convergence of synthetic chemistry, biological evaluation, and computational design is expected to drive further innovations involving this compound in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)